HMG20B Antikörper (AA 1-100)

Produktnummer ABIN1714340

Der Kaninchen Polyklonal Anti-HMG20B-Antikörper wurde für WB, ELISA, IF (cc), IF (p), ICC, IHC (p) und IHC (fro) validiert. Er ist geeignet, HMG20B in Proben von Maus zu detektieren.

Kurzübersicht für HMG20B Antikörper (AA 1-100) (ABIN1714340)

Target: HMG20B (High Mobility Group 20B (HMG20B))

Reaktivität: Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser HMG20B Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunocytochemistry (ICC), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Produktdetails anti-HMG20B Antikörper

Bindungsspezifität: AA 1-100

Kreuzreaktivität: Maus

Homologie: Human,Rat,Cow

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human BRAF35

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200
ICC 1:100-500

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Haltbarkeit: 12 months

Details zu HMG20B

Target: HMG20B (High Mobility Group 20B (HMG20B))

Andere Bezeichnung: BRAF35

Hintergrund:

Synonyms: BRAF25, BRAF35, BRCA 2 Associated Factor 35 kDa, BRCA2 associated factor 35, BRCA2-associated factor 35, High Mobility Group Protein 20B, HM20B_HUMAN, HMG 20B, HMG box containing protein 20B, HMG box-containing protein 20B, HMG domain-containing protein 2, HMG domain-containing protein HMGX2, hmg20b, HMGX2, PP7706, pp8857, SMARCE1 related protein, SMARCE1-related protein, SMARCE1r, sox like, Sox like transcriptional factor, Sox-like transcriptional factor, SOXL, Structural DNA binding protein BRAF35, Structural DNA-binding protein BRAF35, SWI/SNF related, SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily E member 1 related, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related.

Background: The breast cancer susceptibility gene (BRCA1) localizes to chromosome 17q. Mutations within this gene account for approximately 45 % of families with high incidence of breast cancer and at least 80 % of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-13, also confers a high incidence of breast cancer, but unlike BRCA1, BRCA2 does not confer a substantially elevated risk of ovarian cancer. The BRCA2-Associated Factor 35 (BRAF35) protein forms a complex with BRCA2, which associates with condensed chromatin during histone H3 phosphorylation. BRAF35 expression levels are highest in proliferating tissues and parallel BRCA2 expression patterns. The structure of BRAF35 includes a kinesin-like coiled coil domain and a nonspecific DNA binding HMG domain. The chromatin localization of BRAF35 and antibody microinjection studies indicate a role for the BRAF35/BRCA2 complex in cell cycle regulation.

Gen-ID: 10362